PE20030613A1 - Compuestos de 1h-quinolin-2-ona sustituidos - Google Patents

Compuestos de 1h-quinolin-2-ona sustituidos

Info

Publication number
PE20030613A1
PE20030613A1 PE2002001054A PE2002001054A PE20030613A1 PE 20030613 A1 PE20030613 A1 PE 20030613A1 PE 2002001054 A PE2002001054 A PE 2002001054A PE 2002001054 A PE2002001054 A PE 2002001054A PE 20030613 A1 PE20030613 A1 PE 20030613A1
Authority
PE
Peru
Prior art keywords
quinolin
hydroxy
alkyl
compounds
substitute
Prior art date
Application number
PE2002001054A
Other languages
English (en)
Inventor
Helmut Buschmann
Werner Englberger
Babette-Yvonne Kogel
Michael Sattlegger
Michael Przewosny
Hans Schick
Original Assignee
Gruenenthal Chemie
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Gruenenthal Chemie filed Critical Gruenenthal Chemie
Publication of PE20030613A1 publication Critical patent/PE20030613A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D215/20—Oxygen atoms
    • C07D215/22—Oxygen atoms attached in position 2 or 4
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/12—Antidiarrhoeals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/04—Antipruritics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Pain & Pain Management (AREA)
  • Psychiatry (AREA)
  • Psychology (AREA)
  • Urology & Nephrology (AREA)
  • Cardiology (AREA)
  • Vascular Medicine (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Hospice & Palliative Care (AREA)
  • Dermatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Quinoline Compounds (AREA)

Abstract

SE REFIERE A COMPUESTOS DE 1H-QUINOLIN-2-ONA SUSTITUIDOS DE FORMULA I DONDE R1, R2, R3 Y R4 SON ALQUILO C1-C10, CICLOALQUILO C3-C7 CON H, HALO, OH; R5 ES H, ALQUJILO C1-C10, ARILO, HETEROARILO, ENTRE OTROS; R6 ES OH, OR7 DONDE R7 ES ALQUILO C1-C10, CICLOALQUILO, C3-C6; A ES UN PUENTE DE FORMULA -(CH2)3-, -CH2-CH=CH-, -CH2COO-, -CH2CONH-, ENTRE OTROS; X ES UN HETEROCICLO. SON COMPUESTOS PREFERIDOS 2'-(7-CLORO-4-HIDROXI-2-OXO-1,2-DIHIDROQUINOLIN-3-IL)-N-[3''-(N,N-DIMETILAMINOMETIL)-4''-HIDROXI-4''-(m-METOXIFENIL)CICLOHEXIL]ACETAMIDA, 2'-(7-CLORO-4-METOXI-2-OXO-1,2-DIHIDROQUINOLIN-3-IL)-N-[3''-(N,N-DIMETILAMINOMETIL)-4''-HIDROXI-4''-(m-METOXIFENIL)CICLOHEXIL]ACETAMIDA, ENTRE OTROS. SE REFIERE TAMBIEN A UN PROCEDIMIENTO PARA LA PREPARACION. LOS COMPUESTOS MENCIONADOS SON UTILES PARA EL TRATAMIENTO DEL DOLOR
PE2002001054A 2001-10-29 2002-10-28 Compuestos de 1h-quinolin-2-ona sustituidos PE20030613A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
DE10153347A DE10153347A1 (de) 2001-10-29 2001-10-29 Substituierte 1H-Chinolin-2-on-Verbindungen

Publications (1)

Publication Number Publication Date
PE20030613A1 true PE20030613A1 (es) 2003-07-26

Family

ID=7704097

Family Applications (1)

Application Number Title Priority Date Filing Date
PE2002001054A PE20030613A1 (es) 2001-10-29 2002-10-28 Compuestos de 1h-quinolin-2-ona sustituidos

Country Status (11)

Country Link
US (1) US20040224980A1 (es)
EP (1) EP1442021A1 (es)
JP (1) JP2005511567A (es)
AR (1) AR037250A1 (es)
CA (1) CA2465306A1 (es)
DE (1) DE10153347A1 (es)
HU (1) HUP0401831A2 (es)
MX (1) MXPA04004090A (es)
PE (1) PE20030613A1 (es)
PL (1) PL369829A1 (es)
WO (1) WO2003037870A1 (es)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9108948B2 (en) 2006-06-23 2015-08-18 Abbvie Inc. Cyclopropyl amine derivatives
TW200808773A (en) 2006-06-23 2008-02-16 Abbott Lab Cyclopropyl amine derivatives
US9186353B2 (en) 2009-04-27 2015-11-17 Abbvie Inc. Treatment of osteoarthritis pain
US8853390B2 (en) 2010-09-16 2014-10-07 Abbvie Inc. Processes for preparing 1,2-substituted cyclopropyl derivatives
CN112759546B (zh) * 2019-11-06 2022-08-26 复旦大学 3-(二甲氨基甲基)哌啶-4-醇衍生物及其制备方法和药物用途
CN112759587B (zh) * 2019-11-06 2022-12-30 复旦大学 3-(二甲氨基甲基)哌啶-4-醇类衍生物及其制备方法和药物用途
CN112759544B (zh) * 2019-11-06 2022-08-26 复旦大学 3-(二甲氨基甲基)哌啶-4-醇衍生物制备方法和药物用途
WO2021088758A1 (zh) * 2019-11-06 2021-05-14 复旦大学 一类阿片受体激动剂及其制备方法和药物用途
CN112759545B (zh) * 2019-11-06 2022-12-13 复旦大学 3-(二甲氨基甲基)哌啶-4-醇类衍生物及其制备方法和药物用途

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE19525137C2 (de) * 1995-07-11 2003-02-27 Gruenenthal Gmbh 6-Dimethylaminomethyl-1-phenyl-cyclohexanverbin -dungen als Zwischenprodukte zur Herstellung pharmazeutischer Wirkstoffe
PL199781B1 (pl) * 1999-10-25 2008-10-31 Active Biotech Ab Nowe związki pochodne chinoliny, zastosowanie związków pochodnych chinoliny, zawierające je kompozycje farmaceutyczne i sposób ich wytwarzania
DE10049481A1 (de) * 2000-09-29 2002-05-02 Gruenenthal Gmbh Substituierte C-Cyclohexylmethylamin-Derivate

Also Published As

Publication number Publication date
JP2005511567A (ja) 2005-04-28
CA2465306A1 (en) 2003-05-08
DE10153347A1 (de) 2003-05-08
EP1442021A1 (de) 2004-08-04
HUP0401831A2 (hu) 2004-12-28
WO2003037870A1 (de) 2003-05-08
PL369829A1 (en) 2005-05-02
MXPA04004090A (es) 2004-07-08
AR037250A1 (es) 2004-11-03
US20040224980A1 (en) 2004-11-11

Similar Documents

Publication Publication Date Title
GT200200191A (es) Derivados de 1,6-naftiridina y su uso para el tratamiento de la diabetes y trastornos relacionados
ES2141174T3 (es) 4-arilmetiloximetil piperidinas como antagonistas de taquiquinina.
DE58905637D1 (de) Verwendung von Adamantan-Derivaten zur Prävention und Behandlung der cerebralen Ischämie.
PE20020858A1 (es) Indanil aminas aciladas
DE69523169T2 (de) Verwendung von Mangiferin oder seinen Derivaten zur kosmetischen Anwendung
IS8058A (is) Sýklísk súlfónamíð til að hamla gamma seytiasa
ES2116801T3 (es) Empleo de derivados de adamantano para el tratamiento de tinnitus.
ES2164666T3 (es) Compuestos plaguicidas de pirimidina.
PE20030613A1 (es) Compuestos de 1h-quinolin-2-ona sustituidos
PE20030718A1 (es) Lactamas como antagonistas de taquiquininas
DK0647231T3 (da) N-substituerede 3-azabicyclo 3.2.0 heptanderivater til anvendelse som bl.a. neuroleptika
NO893480L (no) Fremgangsmaate for fremstilling av disubstituerte benzylaminer.
PE20040267A1 (es) Tiopirimidinas e isotiazolpirimidinas inhibidoras de quinasas
DE3866665D1 (de) Verwendung von organosilicium-verbindungen zum verdicken von oelen.
DK1189900T3 (da) Heterocykliske aminopyrrolidinderivater som melatonerge lægemidler
PE20021018A1 (es) DERIVADOS DE ß - CARBOLINA
ATE124045T1 (de) Substituierte imidazobenzazepine und imidazopyridoazepine.
AP9901578A0 (en) Sulfonylbenzene compounds as anti-inflammatory/analgesic agents.
EA200100297A1 (ru) Моногидрат гидробромида элетриптана
ES2094545T3 (es) Derivados n-substituidos del 3-azabiciclo(3.2.0)heptano, como neurolepticos etc..
DK74189A (da) Laegemiddel til behandling af mavesaar
IL155958A0 (en) Cysteine protease inhibitors
PE20021099A1 (es) Derivados de c-furano-2-il-metilamina sustituidos
DE69909811T2 (de) Substituierte isoxazolylthiophenverbindungen
WO2001038316A3 (de) Sulfonyloxazolamine und deren verwendung als 5-ht6 rezeptorliganden

Legal Events

Date Code Title Description
FG Grant, registration
FD Application declared void or lapsed